3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Cyclophosphamide
4
Specimen Handling
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
talazoparib
2
selpercatinib
2
palbociclib
2
ivosidenib
2
fludarabine
2
cabozantinib
2
Vemurafenib
2
Topotecan
2
Temozolomide
2
Sirolimus
2
Nuclear Medicine Department, Hospital
2
Nivolumab
2
LY3023414
2
Filgrastim
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
regorafenib
1
racotumomab
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
CLR1404
×
Genitourinary
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled